Navigation Links
Mayo Clinic study: PSA test valuable in predicting biopsy need, low-risk prostate cancer
Date:10/21/2011

ROCHESTER, Minn. -- The prostate-specific antigen test, commonly known as the PSA test, is valuable in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer, a Mayo Clinic study has found. The findings were released today during a meeting of the North Central Section of the American Urological Association (http://www.ncsaua.org/default.aspx) in Rancho Mirage, Calif.

"The decision to use the PSA test is best made by the patient, in consultation with his doctor," says R. Jeffrey Karnes, M.D. (http://www.mayoclinic.org/bio/12463493.html), a Mayo Clinic urologist and co-author of the paper, "Baseline PSA in Men Ages 40 - 60 Predicts Risk of Subsequent and Low-Risk Prostate Cancer in a Patient Cohort."

"One outstanding question has been the PSA test's value as a predictor of the need for a biopsy and future development of low-risk cancer,'' Dr. Karnes says. "Our study found a clear link between the test and these next steps in the prostate cancer continuum of care."

Since 1990, more than 600 men between ages 40 and 79 have been followed prospectively for prostate outcomes. The study found that men in their 40s with a baseline PSA at or above the median PSA were much more likely to undergo a biopsy and be diagnosed with low-risk prostate cancer (http://www.mayoclinic.org/prostate-cancer/); a similar trend was found for men in their 50s. However, the majority of tumors (89 percent) found in both age groups were classified as "low risk."

A PSA test is a common way for physicians to determine a patient's potential risk of developing prostate cancer. The test measures the amount of PSA, a protein produced by cells of the prostate gland, in the patient's blood.

Elevated PSA levels may result from a number of factors, including benign prostate enlargement or inflammation of the urinary tract, which is why additional tests are used in conjunction with the PSA test. For example, if the patient's physician suspects cancer, a biopsy of prostate cells likely will be ordered to confirm the diagnosis.

The PSA test is not without controversy: Recent draft recommendations from the U.S. Preventive Services Task Force suggest that the test may not save lives.

"As we continue to refine our approach to diagnosing and treating prostate cancer, we believe the findings of this study will help clinicians and their patients make informed decisions," Dr. Karnes says.


'/>"/>
Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. The West Clinic Joins Cancer Clinics of Excellence (CCE)
2. Stethoscope App gives iPhone New Clinical Skills
3. Mayo Clinic responsible for $22 billion in economic impact, including $9.6 billion in Minnesota
4. Sunquest Introduces Integrated Clinical Environment Physician Portal Solution in US
5. Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
6. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
7. Sunquest Completes System-Wide Implementation at Cleveland Clinic Hospital Laboratories
8. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
9. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland
10. UCLA Health System Presents: How to Successfully Implement a Clinical Portal
11. International Merchant Advisors CEO Mel Roseman to Discuss New Medical Marijuana Clinics Live on CBS Radio Networks Big Biz Show February 22, 2010 at 1:40 pm PST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... , ... March 01, 2017 , ... After a long ... a spring cleanse. While juice cleanses and workouts top the detox categories, there is ... or physical regime. The Kerry Gaynor Method’s Vital Lung Detox is an herbal-based formula ...
(Date:3/1/2017)... , ... March 01, 2017 , ... ... PurThread’s permanently embedded anti-odor solution to cotton knit and woven fabrics. , ... while maintaining the luxurious look and feel of cotton. Cotton Incorporated has ...
(Date:3/1/2017)... ... , ... Award-winning medical group Allied Anesthesia today announced that, as of 2016, ... more than one trip per year since 1998. Char was named the Los Angeles ... details of his charitable work. Char has been an Allied Anesthesiologist since 2000. , ...
(Date:3/1/2017)... , ... March 01, 2017 , ... ... announced special pricing in the month of March for treatments aimed at tightening ... special features use on Thermage skin tightening, with 30 percent off all Thermage ...
(Date:3/1/2017)... (PRWEB) , ... March 01, 2017 , ... “Letter of ... of published author, Maria Teresa Hamilton, survivor of the Civil War in El Salvador, ... Christian at the age of fifteen. I dedicated myself to serve in very poor ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... PRUSSIA, Pa. , March 1, 2017  Global ... it has completed the largest ever Chronic Inflammatory Demyelinating ... A nd T reatment with H ... designed to demonstrate the efficacy, safety and tolerability of ... Hizentra ® (Immune Globulin Subcutaneous [Human]), compared with ...
(Date:3/1/2017)... Pharmaceutical Care Management Association (PCMA) issued the following statement ... nomination of Seema Verma as the new ... "The popular Medicare Part D program continues to ... offering an abundance of competing plan choices in each ... and home delivery, the program is a win-win for ...
(Date:3/1/2017)... global  Intraoperative Neuromonitoring (IONM) market  is expected to reach USD 3.6 billion by ... neuromonitoring market is anticipated to witness significant growth in the forecast period, which ... of surgeries. Continue Reading ... ... ...
Breaking Medicine Technology: